DUBLIN--(BUSINESS WIRE)--The "Oral Proteins and Peptides Market (3rd Edition), 2018-2030" report has been added to ResearchAndMarkets.com's offering.
The Oral Proteins and Peptides Market (3rd Edition), 2018-2030 report provides an extensive study on the current market landscape of orally administrable protein / peptide-based therapeutics, featuring a comprehensive discussion on the future potential of this evolving market. The field has captured the interest of several drug developers, including both small to mid-sized players and large companies. While more than half of these pipeline candidates are in the discovery / preclinical stages, around 28% of drug candidates are presently in advanced stages of evaluation (phase II and above).
The growing popularity of this upcoming class of therapeutics has led to the development of several oral protein / peptide-based product candidates for the treatment of a myriad of diseases. In addition, the need for efficient and patient-friendly treatment options for chronic disorders, such as diabetes, is estimated to boost the demand for oral proteins and peptides in the coming years. Despite their clinical and commercial success, oral formulations of protein / peptide-based drugs have been associated with multiple drawbacks, such as concerns related to unwanted enzymatic degradation, inherent structural complexities, high manufacturing costs and low bioavailability.
The aforementioned issues tend to have an impact on the overall efficacy of such products, thereby, limiting their therapeutic potential. This has prompted researchers to develop better technologies in order to improve product stability and therapeutic efficiency. The ongoing innovation has led to the discovery of novel biological targets, strengthening the research pipelines of various companies focused in this domain. Increasing research and development activities, and rising demand for effective drugs with better therapy adherence profiles are anticipated to encourage growth of the global oral proteins and peptides market in the coming years.
One of the key objectives of this study was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as target consumer segments, likely adoption rates and expected pricing, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2018-2030.
In addition, we have provided the likely distribution of the market based on [A] therapeutic areas (autoimmune disorders, bone disorders, digestive and gastrointestinal disorders, hormonal disorders, infectious diseases, metabolic disorders, urogenital disorders and others), [B] molecule type (protein and peptide), [C] technology platforms, [D] key players, and [E] geography (North America (the US, Canada and Mexico), Europe (EU5 countries), Asia-Pacific and RoW). To account for the uncertainties associated with the growth of the oral proteins / peptides market and to add robustness to our model, we have provided three forecast scenarios, portraying conservative, base and optimistic tracks of the market's evolution.
The report features detailed transcripts of interviews held with Dinesh Srinivasan (Director, Anthera Pharmaceuticals), Stig K Hansen (Co-founder and CEO, Carmot Therapeutics), Terry Dyck (CEO, IGY Life Sciences and Technology) and Richard Franklin (Director and CEO, Tarix Orphan). All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions.
Key Topics Covered:
2. Executive Summary
4. Market Overview
5. Key Insights
6. KoL Analysis
7. Key Therapeutic Areas
8. Marketed And Late-Stage Drug Profiles
9. Case Studies: Minirin, Sandimmune And Sollpura
10. Oral Drug Delivery Technology Platforms
11. Product Competitiveness Analysis
12. Funding And Investment Analysis
13. Recent Collaborations
14. Publication Analysis
15. Emerging Trends On Social Media
16. Market Forecast And Opportunity Analysis
17. Case Study: Protein / Peptide Manufacturing
18. Swot Analysis
20. Executive Insights
21. Appendix 1: Tabulated Data
22. Appendix 2: List Of Companies
For more information about this report visit https://www.researchandmarkets.com/research/n3mt2w/oral_proteins_and?w=4